Four Hong Kong Hospitals Approved to Conduct Mainland-Valid Clinical Drug Trials

The Hong Kong Sanatorium and Hospital’s oncology department has been accredited as a duly-qualified clinical drug trial institution and may now undertake mainland-valid National Medical Products Administration (NMPA) approved clinical drug trials on behalf of applicants seeking official drug registration. The granting of this status was announced on 29 April in a joint statement from the NMPA and the Hong Kong Department of Health.

In an additional move, three further Hong Kong hospitals – the Prince of Wales Hospital, the Queen Mary Hospital and the Hong Kong Eye Hospital – have successfully completed their statutory clinical trial review and have been approved to continue conducting NMPA-sanctioned clinical drug trials.

For further details (in Chinese), please access the following link:

Announcement on Matters Concerning Mainland Clinical Drug Trials in Four Medical Institutions in the Hong Kong Special Administrative Region (NMPA Announcement No. 36 [2019])